• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by Wotta Paul

    4/16/21 11:12:05 AM ET
    $CHFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CHFS alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Wotta Paul

    (Last) (First) (Middle)
    12988 VALLEY VIEW ROAD

    (Street)
    EDEN PRAIRIE MN 55344

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/16/2021
    3. Issuer Name and Ticker or Trading Symbol
    CHF Solutions, Inc. [ CHFS ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Principal Accounting Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Incentive Stock Option 01/03/2018 01/03/2028 Common Stock 71 1,470 D
    Incentive Stock Option 01/22/2021 01/22/2031 Common Stock 1,250 9.3 D
    Explanation of Responses:
    Remarks:
    Exhibit 24, Power of Attorney, is attached.
    /s/ Thomas Lynch, by Power of Attorney 04/16/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CHFS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHFS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CHFS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuwellis to Advance Treatment of Critically-Ill Children and Babies Under $1.7 Million NIH Grant

      EDEN PRAIRIE, Minn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Critically-ill children and babies with kidney failure or who are dependent on artificial kidney support currently do not have enough therapeutic options. Nuwellis (NASDAQ:NUWE) plans to fill this unmet need with the development of a fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children. Nuwellis is a medical device company dedicated to transforming care for patients suffering from fluid imbalance. The new device will build on the existing technology of the company's Aquadex SmartFlow® system, and will be funded in part by a $1.7 million grant from the Nati

      8/5/21 8:00:00 AM ET
      $NUWE
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021

      EDEN PRAIRIE, Minn., July 27, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), announced today that its second quarter 2021 financial results will be released on Tuesday, August 10, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the Nuwellis website at http://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 1396749. An audio archive of the webcast will be available following

      7/27/21 4:03:00 PM ET
      $CHFS
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • American Medical Association Issues New CPT Code for Nuwellis' Aquadex Ultrafiltration

      EDEN PRAIRIE, Minn., July 13, 2021 (GLOBE NEWSWIRE) -- In an effort to increase the availability of life-saving ultrafiltration therapy to people experiencing fluid overload, the American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT®) code, 0692T for Therapeutic Ultrafiltration. The new CPT code will come into effect on January 1, 2022, at which time providers can utilize the code when using Aquadex® to deliver ultrafiltration to adults and children (20 kg or more). Aquadex is developed and marketed by Nuwellis, Inc. (NASDAQ:NUWE). A specific code for ultrafiltration was granted after a thorough review and validation that the technology met t

      7/13/21 8:00:00 AM ET
      $NUWE
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    SEC Filings

    See more
    • CHF Solutions, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Nuwellis, Inc. (0001506492) (Filer)

      4/27/21 8:15:21 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by CHF Solutions, Inc.

      DEF 14A - CHF Solutions, Inc. (0001506492) (Filer)

      4/13/21 4:43:22 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CHF Solutions, Inc. filed SEC Form 8-K: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers

      8-K - CHF Solutions, Inc. (0001506492) (Filer)

      4/5/21 5:16:56 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Leadership Updates

    Live Leadership Updates

    See more
    • Nuwellis Announces New Appointments to Leadership Team

      EDEN PRAIRIE, Minn., June 22, 2021 (GLOBE NEWSWIRE) -- Continuing its dynamic growth in support of its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload, Nuwellis, Inc. (NASDAQ:NUWE), formerly CHF Solutions, Inc., today announced the appointment of George Montague as Chief Financial Officer, effective June 28, 2021. Neil P. Ayotte, Esq. also joined the Company as Senior Vice President, General Counsel, Secretary and Chief Compliance Officer on June 7, 2021. "Nuwellis is entering an energizing new phase with significant opportunities in heart failure, pediatrics and critical care. The deep knowledge and ex

      6/22/21 8:00:00 AM ET
      $NUWE
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CHF Solutions Appoints Nestor Jaramillo, Jr. as President and Chief Executive Officer

      EDEN PRAIRIE, Minn., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the appointment of President and Chief Operating Officer Nestor Jaramillo, Jr. to President and Chief Executive Officer (CEO), effective immediately. Predecessor CEO John Erb will continue to serve as the company’s Chairman of the Board. Mr. Jaramillo joined CHF Solutions in May 2019 and has driven the evolution of the company’s therapeutic focus strategy from solely heart failure to an expansion into critical care and pediatrics. His vision to transform the trajectory of cardiorenal disea

      1/19/21 8:00:00 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by Wotta Paul

      3 - CHF Solutions, Inc. (0001506492) (Issuer)

      4/16/21 11:12:05 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by L John Erb

      4 - CHF Solutions, Inc. (0001506492) (Issuer)

      1/26/21 9:23:33 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by P. Thomas Lynch

      4 - CHF Solutions, Inc. (0001506492) (Issuer)

      1/26/21 9:22:39 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CHF Solutions, Inc.

      SC 13G - CHF Solutions, Inc. (0001506492) (Subject)

      3/24/21 11:03:40 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by CHF Solutions, Inc.

      SC 13G - CHF Solutions, Inc. (0001506492) (Subject)

      3/23/21 8:52:19 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - CHF Solutions, Inc. (0001506492) (Subject)

      2/16/21 9:55:44 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Financials

    Live finance-specific insights

    See more
    • Nuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021

      EDEN PRAIRIE, Minn., July 27, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), announced today that its second quarter 2021 financial results will be released on Tuesday, August 10, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the Nuwellis website at http://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 1396749. An audio archive of the webcast will be available following

      7/27/21 4:03:00 PM ET
      $CHFS
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care